

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 4)*

La Jolla Pharmaceutical Company

(Name of Issuer)

Common Stock, par value \$.01 per Share

(Title of Class of Securities)

503459109
(CUSIP Number)

Jose M. de Lasa, 100 Abbott Park Road
Abbott Park, Illinois 60064-6049; Phone 847 937 8905

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

May 22, 2001

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [].

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Abbott Laboratories
IRS Identification No. 36-0698440

2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3) SEC USE ONLY

4) SOURCE OF FUNDS

Not Applicable

5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e)

6) CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

NUMBER OF	(7) SOLE VOTING POWER
SHARES	2,603,104
BENEFICIALLY	
OWNED BY	(8) SHARED VOTING POWER
EACH	0
REPORTING	
PERSON WITH	(9) SOLE DISPOSITIVE POWER
	2,603,104
	(10) SHARED DISPOSITIVE POWER
	0

11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

2,603,104

12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES (SEE INSTRUCTIONS)

13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

7.4% (see Item 5 below)

14) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

The following information amends and supplements the Schedule 13D filed on January 2, 1997 (the "Schedule 13D"), the First Amendment to the Schedule 13D filed on September 26, 1997, the Second Amendment to the Schedule 13D filed on December 17, 1998, and the Third Amendment to the Schedule 13D filed on April 17, 2001 (the "Third Amendment"). Capitalized terms used herein but not otherwise defined shall have the meanings described in the Schedule 13D.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

(a) As of May 22, 2001, Abbott was the beneficial owner of 2,603,104 shares of Common Stock (the "Shares"), representing approximately 7.4% of the outstanding shares of the Common Stock.

(b) Abbott has sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the Shares.

(c) In addition to the sales described in Item 5 of the Third Amendment, Abbott has effected the following open market sales of the Common Stock in the past 60 days:

Date -----	Number of Shares Sold -----	Average Price Per Share -----
April 19, 2001	25,000	\$5.20
April 20, 2001	7,500	\$5.20
April 30, 2001	30,000	\$5.25
May 1, 2001	5,000	\$5.20
May 2, 2001	5,000	\$5.40
May 7, 2001	5,000	\$5.61
May 8, 2001	10,000	\$5.65
May 11, 2001	10,000	\$5.60
May 14, 2001	10,000	\$5.7975
May 15, 2001	12,500	\$5.9100
May 16, 2001	32,500	\$6.2785
May 17, 2001	170,000	\$7.291765
May 18, 2001	5,000	\$7.26
May 21, 2001	9,000	\$7.5733
May 22, 2001	10,000	\$7.5100

(d) No one other than Abbott is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from a sale of, the Shares.

(e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Abbott Laboratories

DATED: May 23, 2001

By: /s/ Thomas C. Freyman

Thomas C. Freyman, Senior Vice
President, Finance and Chief
Financial Officer